Walgreens Find Care™ Platform Introduces Chronic Care Management for Patients with Diabetes, Asthma and COPD
One year since launch, several new partners and health care offerings have been added to Walgreens Find Care*
Walgreens shared it has expanded the Walgreens Find Care™ platform to now include chronic care management, featuring connected devices and digital therapeutic solutions for patients with diabetes, asthma and chronic obstructive pulmonary disease (COPD). In addition, one year since launch, several new health care offerings from existing and new partners have been added to the platform.
To further meet the needs of the 30 million adults living with type I or type 2 diabetes, the 25 million U.S. adults and children living with asthma, and the more than 15 million adults with COPD, Walgreens Find Care has added leading diabetes, asthma and COPD device manufacturers, Dexcom and Propeller Health, to its digital platform. Through these new collaborations, Walgreens Find Care users with diabetes, asthma or COPD can learn how to simplify and centralize critical health information with state-of-the-art health monitoring devices.
“Our research shows that Walgreens customers are looking for new, convenient and affordable ways to understand and manage their health care needs,” said Giovanni Monti, vice president and director of health care innovation, Walgreens Boots Alliance, Inc. “Walgreens Find Care delivers on our commitment to help customers improve their health by bringing together curated, proven, omnichannel health care solutions. We believe that by integrating connected care devices, digital therapeutics and the pharmacy experience, we’ll help individuals better manage their chronic conditions while also lowering the overall cost of care.”
The User Experience
On the Walgreens Find Care platform, diabetes patients can learn how to better manage their condition with the Dexcom G6 Continuous Glucose Monitoring (CGM) System. The Dexcom CGM uses a slim sensor to continuously measure glucose levels just beneath the skin and send data wirelessly to a display device though a transmitter, giving patients real-time glucose data without the need to prick their finger. The water-resistant sensor can be worn up to 10 days, and patients will be able to share data with their family or care team. Once the sensor is active, patients can also receive customizable alerts & alarms warning of pending highs/lows. Dexcom CGM is proven to lower A1C and reduce hypoglycemic events.
*The full press release can be found here.
Dexcom is a 2019 National Strategic Partner of DiabetesSisters. DiabetesSisters shares information they provide that is useful to our community; however, the relationship does not influence the decisions or opinions of DiabetesSisters, its governing board or staff.